Advertisement

Surgery pp 2005-2035 | Cite as

Benign and Malignant Diseases of the Breast

  • Helen A. Pass

Abstract

Appreciation of the embryological development, anatomy, and physiology of the breast is critical for the rational evaluation and treatment of both benign and malignant breast disease. The breast develops from the ectodermally derived milk streak. Early in fetal life, the milk streak extends from the axilla to the pubis (Fig. 96.1). At the end of the first trimester, all but the pectoral portion of the milk streak atrophies, leaving the nipple bud. The ducts and lobules form from ingrowth of the ectoderm from the nipple surface. Breast development continues in puberty because of an interplay of mammotrophic hormones. By the age of 20, the breast has reached its greatest development. By 40, it begins to undergo atrophic change.

Keywords

Breast Cancer Sentinel Lymph Node Axillary Lymph Node Dissection National Comprehensive Cancer Network Phyllode Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–1467.CrossRefGoogle Scholar
  2. 2.
    Ottman R, King M, Pike M, Henderson B. Practical guide for estimating risk for familial breast cancer. Lancet 1983;2:556–558.PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson D. Genetic study of breast cancer: identification of a high risk group. Cancer (Phila) 1974;34:1090–1097.PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson D, Badzioch M. Bilaterality in familial breast cancer patients. Cancer (Phila) 1985;56:2092–2098.PubMedCrossRefGoogle Scholar
  5. 5.
    Tokunaga M, Land C, Yamamoto T, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1980. Radiat Res 1987;112:243–272.PubMedCrossRefGoogle Scholar
  6. 6.
    Hildreth N, Shore L, Dvoretsky P. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989;321:146–151.Google Scholar
  7. 7.
    Morris EA. Breast cancer imaging with MRI. Radiol Clin N Am 2002:40:443–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–151.PubMedGoogle Scholar
  9. 9.
    Gail M, Brinton L, Byar D, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–1886.PubMedCrossRefGoogle Scholar
  10. 10.
    National Cancer Institute, http://cancertrials.nci.nih.gov/ 1998.Google Scholar
  11. 11.
    Lynch HT. Introduction to breast cancer genetics. In: Lynch HT, ed. Genetics and Breast Cancer. New York: Van Nostrand Reinhold, 1992:1–13.Google Scholar
  12. 12.
    Miki Y, Swensen J, Shattuck-Eiden D, et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66.PubMedCrossRefGoogle Scholar
  13. 13.
    Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature (Lond) 1995;378:789–792.PubMedCrossRefGoogle Scholar
  14. 14.
    Kriege MS, Brekelmans C, Boetes C, et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 7/2004;351:427–437.PubMedCrossRefGoogle Scholar
  15. 15.
    Claus EB, Schildkraut J, Iversen ES Jr, et al. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 1998;90:1824–1829.PubMedCrossRefGoogle Scholar
  16. 16.
    Brody LC, Biesecker BB. Breast cancer susceptibility genes: BRCA1 and BRCA2. Rev Mol Med 1998;77:208–226.Google Scholar
  17. 17.
    Narod SA, Reuteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12–q23. Lancet 1991;338:82–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Akashi-Tanaka S, Fukutomi T, Tukami A, et al. Male breast cancer in patients with a familial history of breast cancer. Surg Today 1996;26:975–979.PubMedCrossRefGoogle Scholar
  19. 19.
    Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994;7:103–107.PubMedCrossRefGoogle Scholar
  20. 20.
    Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project PI study. J Natl Cancer Inst 1998;90:1371–1388.PubMedCrossRefGoogle Scholar
  21. 21.
    Fisher B, Costantino JP, Redmond C, et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 1989;320:479–484.PubMedGoogle Scholar
  22. 22.
    Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without Tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4:459–471.PubMedGoogle Scholar
  23. 23.
    Mouridsen H, Palshof T, Patterson J, et al. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978;5:137–141.CrossRefGoogle Scholar
  24. 24.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with Tamoxifen: preliminary findings from the Italian Tamoxifen Prevention Study. Lancet 1998;352:93–97.PubMedGoogle Scholar
  25. 25.
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen randomised chemoprevention trial. Lancet 1998;352:98.PubMedGoogle Scholar
  26. 26.
    Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10(4):337–344.PubMedCrossRefGoogle Scholar
  27. 27.
    Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women results from MORE. JAMA 1999;281:2189–2197.PubMedCrossRefGoogle Scholar
  28. 28.
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Thomas DB, Gao DL, Self SG, et al. Randomized trial of breast self examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst 1997;89:355–365.PubMedCrossRefGoogle Scholar
  30. 30.
    Boyd NF, Sutherland HF, Fish EB, et al. Prospective evaluation of physical examination of the breast. Am J Surg 1981;142:331.PubMedCrossRefGoogle Scholar
  31. 30a.
    Boyd NF, Sutherland HF, Fish EB, et al. Prospective evaluation of physical examination of the breast. Am J Surg 1981;142:1477.CrossRefGoogle Scholar
  32. 31.
    Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study 2: breast cancer detection and death rates among women 50 to 59 years. Can Med Assoc J 1992;147:1477.Google Scholar
  33. 32.
    Ciatto J, Catalion L, Distante V. Nonpalpable breast lesions detected with mammography: review of 512 consecutive cases. Radiology 1987;165:99–102.PubMedGoogle Scholar
  34. 33.
    Feig SA, Kopans DB, Sickles EA, et al. Rationale for annual screening mammography for women ages 40–49. Breast Dis 1998;10(3–4):13–21.PubMedGoogle Scholar
  35. 34.
    Morrow M. Surgery in the elderly patient, I: breast disease in elderly women. Surg Clin N Am 1994;74:145.PubMedGoogle Scholar
  36. 35.
    Rimer BK, Ross E, Cristinzio S. Older women’s participation in breast screening. J Gerontol 1992;47:85.PubMedGoogle Scholar
  37. 36.
    Wilson TE, Helvie MA, August DA. Breast imaging: breast cancer in elderly patients, early detection with mammography. Radiology 1994;190:203.PubMedGoogle Scholar
  38. 37.
    American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). Reston, VA: American College of Radiology, 1993.Google Scholar
  39. 37a.
    Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. NEJM 2005;252:1773–1783.CrossRefGoogle Scholar
  40. 38.
    Liberman L, Morris E, Joo-Young Lee M. et al. Breast lesions detected on MR imaging: features and positive predictive value. Am J Roentgenol 2002;179:171–178.Google Scholar
  41. 39.
    Liberman L. Breast cancer screening with MRI: what are the data for patients at high risk? N Engl J Med 7/2004;351:497–500.PubMedCrossRefGoogle Scholar
  42. 40.
    Clinical diagnosis, breast cancer [session 36]. Proceedings of the Society of Nuclear Medicine, 50th Annual Meeting, June 21–25, 2003, New Orleans, LA.Google Scholar
  43. 41.
    Schmidt RA. Stereotactic breast biopsy. CA Cancer J Clin 1994;44:172–191.PubMedCrossRefGoogle Scholar
  44. 42.
    Al-Sobhi S, Helvie MA, Pass HA, Chang AE. Extent of lumpectomy for breast cancer after diagnosis by stereotactic core versus wire localization biopsy. Ann Surg Oncol 1999;6:330–335.PubMedCrossRefGoogle Scholar
  45. 43.
    Dronkers DJ. Stereotaxic core biopsy of breast lesions. Radiology 1992;183:631–634.PubMedGoogle Scholar
  46. 44.
    Parker SH, Lovin JD, Jobe WE, et al. Nonpalpable breast lesions: stereotactic automated large-core biopsies. Radiology 1991;180:403–407.PubMedGoogle Scholar
  47. 45.
    Jackman RJ, Nowels KW, Shepard MJ, et al. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia. Radiology 1994;193:91–95.PubMedGoogle Scholar
  48. 46.
    Liberman L, Cohen MA, Dershaw DD, et al. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. Am J Roentgenol 1995;164:1111–1113.Google Scholar
  49. 47.
    Jackman RJ, Finkelstein SI, Marzoni FA. Stereotaxic large-core needle biopsy of histologically benign, nonpalpable breast lesions: false-negative results and failed follow up. Radiology 1995;193:91–95.Google Scholar
  50. 48.
    Parker S, Burbank F, Jackman RJ, et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology 1994;193:359–364.PubMedGoogle Scholar
  51. 49.
    Smith BL, Souba WW. Algorithm and explanation: assessment and management of breast complaints. Common Clin Prob 1995:1–17.Google Scholar
  52. 50.
    Gately CA, Mottola J, Ruiz CA et al. Reassurance in the treatment of mastalgia. Br J Hosp Med 1990;43(5):330–332.Google Scholar
  53. 51.
    Boyd NF, McGuire V, Shannon P, et al. Effect of a low fat high carbohydrate diet on symptoms of cyclic mastopathy. Lancet 1998;2(8603):128–132.Google Scholar
  54. 52.
    Pashby NL, Mansel RE, Hughes LE, et al. A clinical trial of evening primrose oil in mastalgia. Br J Surg 1981;68:801.CrossRefGoogle Scholar
  55. 53.
    Baker H, Snedecor P. Clinical trial of danazol for benign breast disease. Am Surg 1979;45:727.PubMedGoogle Scholar
  56. 54.
    Mansel R, Preece P, Hughes L. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg 1978;65:724.PubMedCrossRefGoogle Scholar
  57. 55.
    Devitt JE. Management of nipple discharge by clinical findings. Am J Surg 1985;149:789.PubMedCrossRefGoogle Scholar
  58. 56.
    Leis HP Jr, Greene FL, Cammarata A, et al. Nipple discharge: surgical significance. South Med J 1988;81:20.PubMedCrossRefGoogle Scholar
  59. 57.
    Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill-Livingstone, 1987.Google Scholar
  60. 58.
    Dixon JM, Dobie V, Laub J, et al. Assessment of the acceptability of conservative management of fibroadenoma of the breast. Br J Surg 1996;83:264–265.PubMedCrossRefGoogle Scholar
  61. 59.
    Fleming ID, Cooper JS, Henson DE, et al. Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven, 1997:171–178.Google Scholar
  62. 60.
    Van Lancker M, Goor C, Sacre R, et al. Patterns of axillary lymph node metastasis in breast cancer. Am J Clin Oncol 1995;18:267–272.PubMedCrossRefGoogle Scholar
  63. 61.
    Frykberg ER, Bland KI. Management of in situ and minimally invasive breast carcinoma. World J Surg 1994;18:45.PubMedCrossRefGoogle Scholar
  64. 62.
    Page DL, Dupont W, Rogers L, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer (Phila) 1982;49:751–758.PubMedCrossRefGoogle Scholar
  65. 63.
    Rosen P, Brown D, Kinne D. The clinical significance of preinvasive breast carcinoma. Cancer (Phila) 1980;46:919–925.PubMedCrossRefGoogle Scholar
  66. 64.
    Fisher B, Costantino JP, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328:1581–1586.PubMedCrossRefGoogle Scholar
  67. 65.
    Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer (Phila) 1978;42:737–769.PubMedCrossRefGoogle Scholar
  68. 66.
    Alpers C, Wellings S. The prevalence of carcinoma in situ in normal and cancer-associated breast. Hum Pathol 1985;16:796–807.PubMedCrossRefGoogle Scholar
  69. 67.
    Bartow S, Pathak D, Black W, Key C, Teaf S. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. Cancer (Phila) 1987;60:2751–2760.PubMedCrossRefGoogle Scholar
  70. 68.
    Silverstein MJ, Waisman JR, Gierson ED, Colburn W, Gamagami P, Lewinsky B. Radiation therapy for intraductal carcinoma: is it an equal alternative? Arch Surg 1991;126:424–427.PubMedGoogle Scholar
  71. 69.
    Kinne D, Petrek J, Osborne M, Fracchia A, De Palo A, Rosen PP. Breast carcinoma in situ. Arch Surg 1989;124:33–36.PubMedGoogle Scholar
  72. 70.
    Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for T1a breast carcinoma: is it indicated? Cancer (Phila) 1994;73:664–667.PubMedCrossRefGoogle Scholar
  73. 71.
    Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Breast and Bowel Project B-l 7. J Clin Oncol 1998;16:441–452.PubMedGoogle Scholar
  74. 72.
    Lagios MD, Margolin FR, Westdahl PR, et al. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer (Phila) 1989;63:618.PubMedCrossRefGoogle Scholar
  75. 73.
    Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818–1822.PubMedCrossRefGoogle Scholar
  76. 73a.
    Silverstein MJ. The University of Southern California/Van Nuys Prognostic Index in Ductal Carcinoma in Situ of the Breast Second Edition Silverstein MJ, Recht, A, and Lagios MD. Editors, Chapter 45, Lippincott, Williams & Wilkins, Philadelphia 2002.Google Scholar
  77. 74.
    Wolmark N, Dignam J, Fisher B. The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): preliminary results of NSABP protocol B-24 [abstract]. Br Cancer Res Treat 1998;50:227.Google Scholar
  78. 75.
    Schwartz G, Feig S, Rosenberg A. Staging and treatment of clinically occult breast cancer. Cancer (Phila) 1984;53:1379.PubMedCrossRefGoogle Scholar
  79. 76.
    Frykberg E, Santiago F, Betsill W, O’Brien P. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet 1987;164:285–301.PubMedGoogle Scholar
  80. 77.
    McDivitt R, Hutter R, Foote F, Stewart F. In situ lobular carcinoma. A prospective follow-up study indicating cumulative patient risks. JAMA 1967;201:82–86.PubMedCrossRefGoogle Scholar
  81. 78.
    Rosen P, Lieberman P, Braun D. Lobular carcinoma in situ of the breast. Am J Surg 1978;2:225–251.Google Scholar
  82. 79.
    Page DL, Jensen RA. Evaluation and management of high risk and premalignant lesions of the breast. World J Surg 1994;18:32.PubMedCrossRefGoogle Scholar
  83. 80.
    Rosen PP, Kosloff C, Lieberman P, et al. Lobular carcinoma in situ of the breast: detailed analysis of 99 patients with average follow-up of 24 years. Am J Pathol 1978;2:225.CrossRefGoogle Scholar
  84. 81.
    Fisher ER, Fisher B. Lobular carcinoma of the breast: an overview. Ann Surg 1977;185:377.PubMedCrossRefGoogle Scholar
  85. 82.
    Broca PP. Traite des Tumeurs. Paris: Asselin, 1866.Google Scholar
  86. 83.
    Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT, Bottomley RH. Tumor variation in families with breast cancer. JAMA 1972;222:1631–1635.PubMedCrossRefGoogle Scholar
  87. 84.
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265–271.PubMedGoogle Scholar
  88. 85.
    Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993;52:678.PubMedGoogle Scholar
  89. 86.
    Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage [see comments]. Cancer (Phila) 1996;77:697–709.PubMedCrossRefGoogle Scholar
  90. 87.
    Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994;7:103–107.PubMedCrossRefGoogle Scholar
  91. 88.
    Kauff ND, Sutagopan JM, Robson ME, et al. Risk reducing salpingooophorectomy in women with a BRCA 1 or BRCA 2 mutation. N Engl J Med 2002;346:1609–1615.PubMedCrossRefGoogle Scholar
  92. 89.
    Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969;71:747–752.PubMedGoogle Scholar
  93. 90.
    Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:2984–2986.PubMedGoogle Scholar
  94. 91.
    Brownstein MH, Wolf M, Bikowski JB. Cowden’s disease: a cutaneous marker of breast cancer. Cancer (Phila) 1978;41:2393–2398.PubMedCrossRefGoogle Scholar
  95. 92.
    Williard W, Borgen P, Bol R, Tiwari R, Osborne M. Cowden’s disease: a case report with analyses at the molecular level. Cancer (Phila) 1992;69:2969–2974.PubMedCrossRefGoogle Scholar
  96. 93.
    Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22*23. Nature (Lond) 1988;336:577–580.PubMedCrossRefGoogle Scholar
  97. 94.
    Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxiatelangiectasia in the United States. Am J Hum Genet 1986;39:573–583.PubMedGoogle Scholar
  98. 95.
    Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185–187.PubMedCrossRefGoogle Scholar
  99. 96.
    Struewing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995;57:1–7.PubMedGoogle Scholar
  100. 97.
    Halsted W. The results of operations cure of cancer of the breast performed at Johns Hopkins Hospital. Johns Hopkins Hosp Bull 1894;4:497–555.Google Scholar
  101. 98.
    Say C, Donegan WL. A biostatistical evaluation of complications from mastectomy. Surg Gynecol Obstet 1974;138:370–376.PubMedGoogle Scholar
  102. 99.
    Forrest A, Roberts M, Cant E. Simple mastectomy and pectoral node biopsy: the Cardiff-St. Mary’s Trial. World J Surg 1977;1:320–323.PubMedCrossRefGoogle Scholar
  103. 100.
    Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6.PubMedGoogle Scholar
  104. 101.
    Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized clinical trial. Eur J Cancer 1990;26:668.PubMedCrossRefGoogle Scholar
  105. 102.
    Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822.PubMedGoogle Scholar
  106. 103.
    Lagios MD, Westdahl PR, Rose M. The concept and implications of multicentricity in breast carcinoma. Pathol Annu 1981;16:83–102.PubMedGoogle Scholar
  107. 104.
    Holland R, Velig S, Mravunac M, Hendricks J. Histologic multifocality of Tis, Tl-2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer (Phila) 1985;56:979–990.PubMedCrossRefGoogle Scholar
  108. 105.
    Harris J, Recht A. Conservative surgery and radiotherapy. In: Harris J, Hellman S, Henderson IC, Kinne D, eds. Breast Diseases. Philadelphia: Lippincott, 1991:399–404.Google Scholar
  109. 106.
    Vicini F, Eberlein T, Connolly J, et al. The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy. Ann Surg 1991;214:200–205.PubMedCrossRefGoogle Scholar
  110. 107.
    Kurtz J, Jacquemier J, Amalric R, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990;8:591–598.PubMedGoogle Scholar
  111. 108.
    NIH Consensus Development Conference Treatment of early-stage breast cancer. NIH Consensus Statement 1990;8:1–19.Google Scholar
  112. 109.
    Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391–401.PubMedCrossRefGoogle Scholar
  113. 110.
    Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271–276.PubMedCrossRefGoogle Scholar
  114. 111.
    Prognostic importance of occult axillary lymph node microme-tastases from breast cancers. International (Ludwig) Breast Cancer Study Group [see comments]. Lancet 1990,335:1565–1568.Google Scholar
  115. 112.
    Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303–306.PubMedGoogle Scholar
  116. 113.
    Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction: comparison between MUC1 and mRNA and keratin 19 mRNA amplification. Am J Pathol 1996;148:649–656.PubMedGoogle Scholar
  117. 114.
    Menes TS, Tartter PI, Mizrachi H et al. Breast cancer patients with pN0 and pN1 sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg 3/2005;(3):323–327.CrossRefGoogle Scholar
  118. 115.
    Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090–2100.PubMedGoogle Scholar
  119. 116.
    Thor AD, Berry DA, Budman DR, et al. Erb-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90(18):1346–1360.PubMedCrossRefGoogle Scholar
  120. 117.
    Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473–478.PubMedGoogle Scholar
  121. 118.
    Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil [see comments]. J Clin Oncol 1996;14:1982–1992.PubMedGoogle Scholar
  122. 119.
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479–484.PubMedGoogle Scholar
  123. 120.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [see comments]. J Natl Cancer Inst 1996;88:1529–1542.PubMedCrossRefGoogle Scholar
  124. 121.
    Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352(9132):930–942.Google Scholar
  125. 122.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women [see comments]. Lancet 1992;339:71–85.Google Scholar
  126. 123.
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081–1092.PubMedCrossRefGoogle Scholar
  127. 124.
    Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987;10:387–395.PubMedCrossRefGoogle Scholar
  128. 125.
    Slamon DJ, Leyland-Jones B, Shaks S, et al. Use of chemotherapy plus a monoclonal antibody against Her 2 for metastatic breast cancer that overexpresses Her 2. N Engl J Med 2001;344( 11 ):783–792.PubMedCrossRefGoogle Scholar
  129. 126.
    Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer [see comments]. N Engl J Med 1996;334:1356–1361.PubMedCrossRefGoogle Scholar
  130. 127.
    Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496.PubMedGoogle Scholar
  131. 128.
    Arthur DW, Morris MM, Vicini FA. Breast cancer: new radiation treatment options. Oncology 2004(13):1621–1629.Google Scholar
  132. 129.
    Bedwinek JM, Lee J, Fineberg B, Ocwieza M. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer (Phila) 1981;47:2232–2235.PubMedCrossRefGoogle Scholar
  133. 130.
    Stefanik D, Goldberg R, Byrne P, et al. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1985;3:660–665.PubMedGoogle Scholar
  134. 131.
    Jones JM, Ribeiro GG. Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy [see comments]. Clin Radiol 1989;40:204–208.PubMedCrossRefGoogle Scholar
  135. 132.
    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial [see comments]. N Engl J Med 1997;337:949–955.PubMedCrossRefGoogle Scholar
  136. 133.
    Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer [see comments]. N Engl J Med 1997;337:956–962.PubMedCrossRefGoogle Scholar
  137. 134.
    Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889–3894.PubMedGoogle Scholar
  138. 135.
    Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992;19:278–285.PubMedGoogle Scholar
  139. 136.
    Hortobagyi GN, Ames FC, Buzdar AU, et al. Managements of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer (Phila) 1988;62:2507–2516.PubMedCrossRefGoogle Scholar
  140. 137.
    Lippman ME, Sorace RA, Bagley CS, Danforth DW Jr, Lichter A, Wesley MN. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. Monogr Natl Cancer Inst 1986:1:153–159.Google Scholar
  141. 138.
    Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986;4:1765–1771.PubMedGoogle Scholar
  142. 139.
    Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast, II: Inflammatory carcinoma. Cancer (Phila) 1994;74(suppl 1):466–476.PubMedCrossRefGoogle Scholar
  143. 139a.
    Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Annals of Surgical Oncology 2002;9:217–219.CrossRefGoogle Scholar
  144. 140.
    Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: protocol 19 Aredia Breast Cancer Study Group [see comments]. N Engl J Med 1996;335:1785–1791.PubMedCrossRefGoogle Scholar
  145. 141.
    Paget J. Disease of the mammary areola preceding cancer of the mammary gland. St Bart Hosp Rep 1874;10:79–89.Google Scholar
  146. 142.
    Pierce LJ, Haffty BG, Solin LJ, et al. The conservative management of Paget’s disease of the breast with radiotherapy. Cancer (Phila) 1997;80:1065–1072.PubMedCrossRefGoogle Scholar
  147. 143.
    Harris J, Morrow M, Bonadonna G. Cancer of the breast. In: Harris J, Lippman M, Morrow M, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996:129.Google Scholar
  148. 144.
    Campana F, Forquet A, Ashby M. Presentation of axillary lymphadenopathy without detectable breast primary: experience at Institut Curie. Radiol Oncol 1989;15:321–325.CrossRefGoogle Scholar
  149. 145.
    Mazze RI, Kallean B. Reproductive outcome after anaesthesia and operation during pregnancy: a registry study of 5405 cases. Am J Obstet Gynecol 1980;138:1165.Google Scholar
  150. 146.
    Karlsson P, Holmberg E, Johansson KA, Kindblom LG, Carstensen J, Wallgren A. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996;38:25–31.PubMedCrossRefGoogle Scholar
  151. 147.
    Hayward J. The Guy’s trials on “early” breast cancer. World J Surg 1977;1:314.PubMedCrossRefGoogle Scholar
  152. 148.
    Sarrazin D, Le M, Arriagada R, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 1989;14:177.PubMedCrossRefGoogle Scholar
  153. 149.
    Lichter A, Lippman M, Danforth D, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol 1992;10:976.PubMedGoogle Scholar
  154. 150.
    Van Dongen J, Bartelink K, Fentimen I, et al. Randomized clinical trial to assess the value of breast conserving therapy in Stage I and II breast cancer: EORTC 10801 trial. Monogr J Natl Cancer Inst 1992;11:15.Google Scholar
  155. 151.
    Blichert-Toft M, Rose C, Andersen J, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Monogr J Natl Cancer Inst 1992;11:19.Google Scholar
  156. 152.
    Krag D, Harlow S, Weaver D, Ashikaga T. Technique of sentinel node resection in melanoma and breast cancer: probe-guided surgery and lymphatic mapping. Eur J Surg Oncol 1998;24:89–93.PubMedCrossRefGoogle Scholar
  157. 153.
    Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335–339.PubMedCrossRefGoogle Scholar
  158. 154.
    Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer [letter] [see comments]. Lancet 1997;349:1668–1669.PubMedCrossRefGoogle Scholar
  159. 155.
    Giuliano AE. Intradermal blue dye to identify sentinel lymph node in breast cancer (letter; comment), Lancet 1997;350:958.PubMedCrossRefGoogle Scholar
  160. 156.
    Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997;3:336–340.PubMedGoogle Scholar
  161. 157.
    Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864–1867.PubMedCrossRefGoogle Scholar
  162. 158.
    Barnwell JM, Arredondo MA, Kollmorgen D, et al. Sentinel node biopsy in breast cancer. Ann Surg One 1998;126–130.Google Scholar
  163. 159.
    Borgstein PJ, Pijpers R, Comans EF, Van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275–283.PubMedCrossRefGoogle Scholar
  164. 160.
    Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study (see comments). N Engl J Med 1998;339:941–946.PubMedCrossRefGoogle Scholar
  165. 161.
    O’Hea BJ, Hill ADK, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423–427.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Helen A. Pass
    • 1
    • 2
  1. 1.Department of Clinical SurgeryColumbia UniversityColumbia
  2. 2.New York-Presbyterian Hospital/Columbia University Medical CenterNew YorkUSA

Personalised recommendations